Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study is testing a CAR-T cell therapy that targets the CD19 protein on cancer cells in patients with relapsed or hard-to-treat non-Hodgkin lymphoma (NHL), including Burkitt lymphoma and other aggressive B-cell lymphomas. **You may be eligible if...** - You have a diagnosis of relapsed or refractory Burkitt lymphoma or another eligible B-cell lymphoma subtype - You have received at least one prior treatment that included both an anti-CD20 antibody (like rituximab) and an anthracycline chemotherapy - Your disease is measurable on a PET scan - There are no significant amounts of cancer cells circulating in your blood **You may NOT be eligible if...** - Your lymphoma is not CD19-positive - You have active central nervous system lymphoma involvement in certain locations - You have significant organ dysfunction or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.